Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

3 Safe High-Yield Dividend Stocks to Pounce on Now

In today's volatile market, dividend stocks remain one of the safest choices.

Nervous About the Market? 3 Defensive Stock Picks to Consider This August

Nervous About the Market? 3 Defensive Stock Picks to Consider This August

Explore three defensive stock picks from the consumer staples, healthcare, and utilities sectors that offer stability amid market uncertainty in August.

Best Stocks to Buy for Fed Rate Cuts

Best Stocks to Buy for Fed Rate Cuts

Consider these stock and fund picks now that the Federal Reserve's rate-cutting campaign is underway.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

13 Stocks Make Investors $200 Billion Richer As The Rest Collapse

The S&P 500 is down a staggering $3.2 trillion in the market implosion since mid-July. But some investors are dodging the pain.

Investors Business Daily

What Are Wall Street Analysts' Target Price for Abbvie Stock?

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

Secure Decades of Passive Income: 3 Top Dividend Stocks to Buy Now

These companies have consistently paid and increased their dividends, and they have a growing earnings base to support their future payouts.

AbbVie Is About To Have A New Golden Goose As Humira Sales Continue Slowing

AbbVie stock slipped Thursday despite a second-quarter beat that included strong Skyrizi sales and a boost to 2024 earnings guidance.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Highest-Yielding Dividend Kings That Wall Street Loves

3 Highest-Yielding Dividend Kings That Wall Street Loves

A high yield doesn't necessarily translate to a buy. This article bridges the gap by combining high dividend payouts and buy ratings.

Option Volatility And Earnings Report For July 22 - 26

Option Volatility And Earnings Report For July 22 - 26

This week we have Tesla (TSLA), Microsoft (MSFT), Alphabet (GOOGL), Exxon Mobil (XOM), Visa (V), Abbvie (ABBV) and Chipotle Mexican Grill (CMG) all set to report.

AbbVie Earnings Preview: What to Expect

AbbVie Earnings Preview: What to Expect

AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.

Is Abbvie Stock Underperforming the S&P 500?

Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

Down 14% from All-Time Highs, is This Dividend King a Buy on the Dip?

Down 14% from All-Time Highs, is This Dividend King a Buy on the Dip?

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Abbvie Stock: Is Wall Street Bullish or Bearish?

Abbvie Stock: Is Wall Street Bullish or Bearish?

Although Abbvie stock has been lagging behind the broader market over the past year, Wall Street analysts are still moderately bullish about its outlook.

3 Cheapest Dividend Kings To Buy Today

3 Cheapest Dividend Kings To Buy Today

This article covers three buy-rated companies that've increased their dividends for 50+ consecutive years.

Get all your
news in one place.

100’s of premium titles.
One news app.

5 Standout Healthcare Dividend Stocks to Consider Now

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

Investors Business Daily

AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That

AbbVie is "firing on all cylinders," an analyst said Friday after the firm beat first-quarter estimates. But AbbVie stock fell.

Stock Index Futures Climb on Upbeat Big Tech Earnings, U.S. Inflation Data Looms

June S&P 500 E-Mini futures (ESM24) are up +0.63%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.86% this morning as upbeat quarterly results from tech titans Alphabet and Microsoft boosted sentiment, while investors geared up for the release of the Fed’s preferred inflation gauge.

Merck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

Get all your
news in one place.

100’s of premium titles.
One news app.

Fake Botox injections have sickened 22, hospitalized 11, CDC warns

The CDC warned doctors about "counterfeit or mishandled" Botox injections that have caused clusters of illness in the U.S.

Investors Business Daily

The Bad News Heading Into AbbVie's First-Quarter Earnings Report

AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Fake Botox has sickened patients nationwide. Here's what to know — and what to avoid

Public health authorities are investigating reports of counterfeit injections sickening 19 people across nine states. Experts say getting bona fide Botox starts with finding a trustworthy provider.

19 Botched Botox Cases Reported Across 9 States: CDC, FDA Investigate

Officials said that all the incidents involved women who reported sick following the administration of counterfeit Botox injections of AbbVie or those who received injections from unlicensed or untrained individuals in non-healthcare environments.

3 Defensive Stocks for 'Sell in May' Season

Investors can consider adding defensive stocks, such as AbbVie and Verizon, to their equity portfolios in 2024 to help shield against heightened stock market volatility.

The Guardian - UK

Patients in England to be offered daily pill that can halve migraine frequency

Nice approves first oral treatment with Atogepant that can prevent chronic and episodic migraines

International Business Times

Alvotech Aims To Break Open The World's Most Notorious Pharma Market

Alvotech's 2024 plans include several product launches around the world through various partners, but the forthcoming introduction of SIMLANDI® in the U.S. is in a market that is truly in the spotlight.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

290,389 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play